Q4 2026 Alembic Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Alembic Pharmaceuticals Ltd (BOM:533573) reported a 4% year-on-year growth in revenue for Q4 FY 2026, driven by new launches in the US and volume-led growth in APIs and animal health.
- The company's India business delivered a 5% growth for the full year, supported by price-led growth and new launches, particularly in specialty therapies and animal healthcare.
- The Indore facility is fully operational with improving capacity utilization, enhancing supply reliability, logistics, and operating efficiency.
- Alembic Pharmaceuticals Ltd (BOM:533573) launched six new products in the US during the quarter, contributing to the positive growth in the international business.
- The company is focusing on a strategic pivot towards a more execution-led model, emphasizing quality of portfolio, better asset utilization, and selective investments in platforms.
- Pricing pressure, competitive intensity, and supply chain volatility continue to challenge the company's performance.
- The US branded business, including the launch of Pivya, has created a drag on the company's margins, expected to persist for another quarter or two.
- R&D spending increased to 11% of revenue for the quarter, driven by peptide-related development activities, impacting reported EBITDA margins.
- The F2 and F3 facilities remain underutilized pending FDA approvals, adding costs without corresponding revenue.
- The API business faced pricing headwinds, although it delivered modest growth driven primarily by volumes.
Ladies and gentlemen, good day, and welcome to the Q4 FY 2026 earnings conference call of Alembic Pharmaceuticals Limited. We have with us today Mr. Pranav Amin, Managing Director, Mr. G. Krishnan, CFO, Mr. Ajay Kumar Desai, Senior Vice President, Finance, and Ms. Esha Lamba, General Manager, Corporate Development and Investor Relations.
As a reminder, this conference call is only for analyst and institutional investors. All participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star and then zero on your touchtone phone. Please note that this conference is being recorded.
I now hand the conference over to Mr. Pranav Amin, Managing Director. Thank you, and over to you, sir.
Thank you, good evening, everyone. Thank you for joining us at the Alembic Pharmaceuticals Q4 and FY 2026
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
